CM
Create Medicines
- Total Funding
- $122.0M
- Last Round
- $122.0M Series BMay 2026
- Rounds
- 1
About
Clinical-stage biotechnology company pioneering new class of in vivo immune programming therapies.
Summary
It has raised $122.0M in total across 1 round, most recently a $122.0M Series B round in May 2026. Investors include Newpath Management and ARCH Venture Partners.
Funding History
$122.0M
May 2026
